Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Research & Discovery » Genetic Research » Veracyte's Prosigna IDs Breast Cancer Patients Likely to Benefit from Aggressive Chemotherapy

Veracyte's Prosigna IDs Breast Cancer Patients Likely to Benefit from Aggressive Chemotherapy

Mar 02, 2020
|
staff reporter

NEW YORK – A new retrospective study published in NPJ Breast Cancer on Monday suggests that Veracyte's Prosigna breast cancer prognostic gene signature assay can identify the subgroups of patients who are more likely to benefit from aggressive chemotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Same Old Error

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

Own Merits

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Back to Neanderthals

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

PNAS Papers on Small Molecule From Soil Bacteria, Circulating Tumor Cell Chip, More

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.

What's Popular?

In Genetic Research

  1. Irish Traveller Gut Microbiomes Reveal Effect of Lifestyle Change on Microbial Makeup, Disease Risk

  2. Sequencing Study Reveals Role of RIPOR2 Mutation in Adult-Onset Hearing Loss

  3. Polygenic Risk Score Modifies Breast Cancer Risk in Pathogenic Variant Carriers

  4. Genomics England, Sano, Zetta Building Platform to Support Rare Disease Patient Participation

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.